Metagenomi Therapeutics (MGX) Non Operating Income (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Non Operating Income of $1.5 million for Q1 2026, down 46.58% year-over-year from $2.9 million in Q1 2025, and down 81.17% quarter-over-quarter from $8.2 million in Q4 2025.
Metagenomi Therapeutics (MGX) Non Operating Income (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Non Operating Income data on file, last reported at $1.5 million in Q1 2026.
- Non Operating Income for Q1 2026 came in at $1.5 million, down 46.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.0 million (up 1175.91% YoY), and the FY2025 annual result was $8.1 million, up 4006.76% from the prior year.
- Non Operating Income fell to $1.5 million in Q1 2026 per MGX's latest filing, from $8.2 million in the prior quarter.
- Over five years, Non Operating Income peaked at $8.2 million in Q4 2025 and troughed at -$9.5 million in Q4 2024.
- A 4-year average of $2.3 million and a median of $2.9 million in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income tumbled 362.4% in 2024, then surged 5858.0% in 2025.
- A 4-year view of Non Operating Income shows it stood at $3.6 million in 2023, then plunged by 362.4% to -$9.5 million in 2024, then soared by 185.79% to $8.2 million in 2025, then sank by 81.17% to $1.5 million in 2026.
- Business Quant data shows MGX's Non Operating Income at $1.5 million in Q1 2026, $8.2 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 9.35 Mn |
| 10 | Metagenomi Therapeutics | 46.60 Mn | 46.60 Mn | - | 1.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 8.17 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 1.12 Mn |
| Mar 31, 2025 | 2.88 Mn |
| Dec 31, 2024 | -9.52 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 3.93 Mn |
| Mar 31, 2024 | -50,000.00 |
| Dec 31, 2023 | 3.63 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Jun 30, 2023 | 6.85 Mn |
| Mar 31, 2023 | 4.00 Mn |